PPLPHARMA · Piramal Pharma Ltd · Biotechnology & Drugs
Last close, 30 Oct
0.5% below 52-week high
52-week range: as of 30 Oct 2026.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Stock Condition as of 30 Oct 2026 close
Full signal detail →Chart
Fundamentals as of 15 Sep 2026 · the company's own latest record is 47 days old
Revenue (latest Q)
₹2,270 Cr
Revenue YoY
PAT YoY
+15.1%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
6.7
P/S (TTM)
3
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| PPLPHARMA (this stock) | Not meaningful (earnings negative over the last 12 months) | 6.7 | -3.4% | -3.8% | 0.7 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
falling 1q
FII
MF
13.18% (-0.94pp)
falling 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- mediummacroeconomictimes.indiatimes.com· 28 Oct 2026, 09:08 pmAhead of Market: 10 things that will decide stock market action on Wednesday
- lowmanilatimes.net· 28 Oct 2026, 01:58 amPiramal Pharma Limited Announces Results for Q2 and H1 FY27
- highsector policyeconomictimes.indiatimes.com· 23 Jul 2026, 05:29 amPharma stocks slide as Trump's 100% generic drug tariff plan spooks investors
Concalls & investor presentations
AI-generatedKey takeaway: The document provides a transcript of Piramal Pharma Limited's conference call discussing its unaudited financial results for the quarter and half year ended 30 September 2026. The transcript is available on the company's website as required by SEBI regulations. The call included discussions on standalone and consolidated financial performance, though specific figures or management commentary are not detailed in the provided text. The company's registered office, contact information, and stock exchange listings are included in the document. The filing adheres to regulatory requirements for disclosure.
The document is a routine compliance filing with no explicit positive or negative language.
Sourced from an exchange-filed transcript, dated 30 Oct 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Piramal Pharma Limited provided a transcript of its conference call regarding the unaudited financial results for the quarter ended 30th June 2026. The document included details about the call held on 30th July 2026, which discussed both standalone and consolidated financial results. The company referenced a previous communication dated 20th July 2026 and noted that the transcript is accessible on its website. The correspondence was signed by Maneesh Sharma, the Company Secretary and Compliance Officer.
The document presented factual information regarding the conference call and financial results without emphasizing any particular sentiment.
Sourced from an exchange-filed transcript, dated 31 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Piramal Pharma Limited announced its unaudited financial results for the first quarter of FY27, reporting a 17% increase in revenue from operations, reaching ₹2,270 crores compared to ₹1,934 crores in Q1FY26. The company highlighted strong performance across its three business segments: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Piramal Consumer Healthcare (PCH). EBITDA rose by 72% to ₹285 crores, with an EBITDA margin improvement to 12.5% from 8.5%. Management noted that the CDMO segment experienced broad-based growth, while CHG maintained leadership in key therapies. The PCH segment saw robust growth driven by Power Brands and e-commerce. Nandini Piramal, Chairperson, expressed optimism about sustaining revenue growth and EBITDA expansion throughout FY27.
Management emphasized strong performance and growth across all business segments.
Sourced from an exchange-filed presentation, dated 29 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Piramal Pharma Limited provided a transcript of its conference call held on 29th April 2026, discussing the audited financial results for the quarter and year ended 31st March 2026. The document included details about the company's performance and was made available on the company's website. The communication was in accordance with Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The document presented factual information regarding the conference call and financial results.
Sourced from an exchange-filed transcript, dated 30 Apr 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Piramal Pharma Limited announced its audited financial results for Q4 and FY26, reporting a consolidated revenue from operations of ₹8,869 crores, a 3% decrease from FY25. The company noted that revenue growth was impacted by inventory destocking and slower early-stage order inflows. The EBITDA for FY26 was ₹1,135 crores, down 28% year-over-year, with an EBITDA margin of 13%. Management recognized an impairment loss of ₹176 crores related to intangible assets, leading to a net profit after exceptional items of ₹(326) crores. Key highlights included a 17% growth in the Consumer Healthcare segment and a successful acquisition of Kenalog®, which is anticipated to broaden the Complex Hospital Generics portfolio. Nandini Piramal, Chairperson, stated that despite challenges, the company exited FY26 with stronger momentum and positioned for growth in FY27 across all business segments.
The document presented both challenges and positive developments in the company's performance.
Sourced from an exchange-filed presentation, dated 28 Apr 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedPiramal Pharma Limited (PPLPHARMA) reported a net loss of ₹325.94 crore for FY2026, down from a profit of ₹91.13 crore in FY2025, primarily due to a decrease in total income, increased expenses, and exceptional items including impairment losses and labor code implementation costs. The company's net fixed assets increased to ₹9,783.76 crore as of March 31, 2026, driven by capacity additions and foreign currency translation effects. The auditor highlighted key audit matters related to the impairment assessment of goodwill and intangible assets under development, emphasizing the estimation uncertainties involved. The company maintains a D&O insurance policy and has no pending insolvency proceedings or regulatory penalties noted.
- Net loss of ₹325.94 crore in FY2026 due to decreased income, higher expenses, and exceptional items.
- Net fixed assets increased to ₹9,783.76 crore as of March 31, 2026.
- Key audit matter: Impairment assessment of goodwill and intangible assets under development with estimation uncertainties.
- No pending insolvency proceedings or regulatory penalties reported.
Key takeaway: Piramal Pharma reported a significant net loss in FY2026, with key risks centered around impairment estimates and financial performance decline.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (1 item); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceRecent (last 12 months)
The auditor did not audit the financial information of 9 subsidiaries with total assets of ₹3,076.52 Crores and two associates, relying on unaudited financial information provided by management for the consolidated financial statements.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
A fine of Euros 182,001 was imposed on Piramal Critical Care B.V., a step-down wholly owned subsidiary of the Company, by the Audien.
Default / Covenant Breach
1 occurrenceRecent (last 12 months)
The company has undisputed statutory dues in arrears for more than six months as of 31 March 2026, including Goods and Service tax, Excise Duty, and Sales Tax, with amounts unpaid ranging from J in Crores.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
Piramal Pharma Limited has a contingent liability related to disputes with Telangana State Pollution Control Board (TSPCB) and appeals filed in respect of disputed demands including Income Tax, Sales Tax, Central/Excise/Service Tax/Custom/GST, and Labour Matters.
Earlier (1-3 years ago)
The company has contingent liabilities including disputes with Telangana State Pollution Control Board (TSPCB) and appeals filed regarding disputed demands in Income Tax, Sales Tax, Central/Excise/Service Tax/Custom/GST, and Labour Matters. Future cash outflows are determinable only upon receipt of judgments or decisions from pending forums or authorities.
The company has contingent liabilities including disputes with Telangana Pollution Control Board (TPCB) and appeals filed regarding disputed demands in income tax, sales tax, central/excise/service tax, custom/GST, and labour matters. Future cash outflows are determinable only upon receipt of judgments/decisions from pending forums/authorities.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company has transactions with related parties, including associates, as disclosed in the annual report.
Earlier (1-3 years ago)
The company contributed ₹3 Crores to the Bharatiya Janata Party during the year, and ₹3 Crores through electoral bonds in the previous year.
Statutory dues in dispute
1 occurrenceEarlier (1-3 years ago)
The company has statutory dues disputes pending as of March 31, 2024, with specific amounts and details provided for each dispute.